Literature DB >> 15135308

Pharmacological characterization of human excitatory amino acid transporters EAAT1, EAAT2 and EAAT3 in a fluorescence-based membrane potential assay.

Anders A Jensen1, Hans Bräuner-Osborne.   

Abstract

We have expressed the human excitatory amino acid transporters EAAT1, EAAT2 and EAAT3 stably in HEK293 cells and characterized the transporters pharmacologically in a conventional [(3) H]-d-aspartate uptake assay and in a fluorescence-based membrane potential assay, the FLIPR Membrane Potential (FMP) assay. The K(m) and K(i) values obtained for 12 standard EAAT ligands at EAAT1, EAAT2 and EAAT3 in the FMP assay correlated well with the K(i) values obtained in the [(3) H]-d-aspartate assay (r(2) values of 0.92, 0.92, and 0.95, respectively). Furthermore, the pharmacological characteristics of the cell lines in the FMP assay were in good agreement with previous findings in electrophysiology studies of the transporters. The FMP assay was capable of distinguishing between substrates and non-substrate inhibitors and to discriminate between "full" and "partial" substrates at the transporters. Taking advantage of the prolific nature of the FMP assay, interactions of the EAATs with substrates and inhibitors were studied in some detail. This is the first report of a high throughput screening assay for EAATs. We propose that the assay will be of great use in future studies of the transporters. Although conventional electrophysiology set-ups might be superior in terms of studying sophisticated kinetic aspects of the uptake process, the FMP assay enables the collection of considerable amounts of highly reproducible data with relatively little labor. Furthermore, considering that the number of EAAT ligands presently available is limited, and that almost all of these are characterized by low potency and a low degree of subtype selectivity, future screening of compound libraries at the EAAT-cell lines in the FMP assay could help identify structurally and pharmacologically novel ligands for the transporters.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15135308     DOI: 10.1016/j.bcp.2004.02.013

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  19 in total

1.  Probing for improved potency and in vivo bioavailability of excitatory amino acid transporter subtype 1 inhibitors UCPH-101 and UCPH-102: design, synthesis and pharmacological evaluation of substituted 7-biphenyl analogs.

Authors:  Mette N Erichsen; Jeanette Hansen; Josep A Ruiz; Charles S Demmer; Bjarke Abrahamsen; Jesper F Bastlund; Christoffer Bundgaard; Anders A Jensen; Lennart Bunch
Journal:  Neurochem Res       Date:  2014-02-28       Impact factor: 3.996

2.  Characterization of the L-glutamate clearance pathways across the blood-brain barrier and the effect of astrocytes in an in vitro blood-brain barrier model.

Authors:  Hans Cc Helms; Blanca I Aldana; Simon Groth; Morten M Jensen; Helle S Waagepetersen; Carsten U Nielsen; Birger Brodin
Journal:  J Cereb Blood Flow Metab       Date:  2017-02-01       Impact factor: 6.200

3.  Behavioral and synaptic alterations relevant to obsessive-compulsive disorder in mice with increased EAAT3 expression.

Authors:  Claudia Delgado-Acevedo; Sebastián F Estay; Anna K Radke; Ayesha Sengupta; Angélica P Escobar; Francisca Henríquez-Belmar; Cristopher A Reyes; Valentina Haro-Acuña; Elías Utreras; Ramón Sotomayor-Zárate; Andrew Cho; Jens R Wendland; Ashok B Kulkarni; Andrew Holmes; Dennis L Murphy; Andrés E Chávez; Pablo R Moya
Journal:  Neuropsychopharmacology       Date:  2018-12-26       Impact factor: 7.853

4.  Pharmacological identification of a guanidine-containing β-alanine analogue with low micromolar potency and selectivity for the betaine/GABA transporter 1 (BGT1).

Authors:  Anas Al-Khawaja; Jette G Petersen; Maria Damgaard; Mette H Jensen; Stine B Vogensen; Maria E K Lie; Bolette Kragholm; Hans Bräuner-Osborne; Rasmus P Clausen; Bente Frølund; Petrine Wellendorph
Journal:  Neurochem Res       Date:  2014-05-23       Impact factor: 3.996

5.  Effect of ceftriaxone and topiramate treatments on naltrexone-precipitated morphine withdrawal and glutamate receptor desensitization in the rat locus coeruleus.

Authors:  María Carmen Medrano; Aitziber Mendiguren; Joseba Pineda
Journal:  Psychopharmacology (Berl)       Date:  2015-03-20       Impact factor: 4.530

6.  Design and Synthesis of 2,3- trans-Proline Analogues as Ligands for Ionotropic Glutamate Receptors and Excitatory Amino Acid Transporters.

Authors:  Christian B M Poulie; Anna Alcaide; Mikkel Krell-Jørgensen; Younes Larsen; Eloi Astier; Walden E Bjørn-Yoshimoto; Feng Yi; Jed T Syrenne; Morten Storgaard; Birgitte Nielsen; Karla A Frydenvang; Anders A Jensen; Kasper B Hansen; Darryl S Pickering; Lennart Bunch
Journal:  ACS Chem Neurosci       Date:  2019-05-24       Impact factor: 4.418

7.  Exon-skipping splice variants of excitatory amino acid transporter-2 (EAAT2) form heteromeric complexes with full-length EAAT2.

Authors:  Florian M Gebhardt; Ann D Mitrovic; Daniel F Gilbert; Robert J Vandenberg; Joseph W Lynch; Peter R Dodd
Journal:  J Biol Chem       Date:  2010-08-05       Impact factor: 5.157

Review 8.  The importance of the excitatory amino acid transporter 3 (EAAT3).

Authors:  Walden E Bjørn-Yoshimoto; Suzanne M Underhill
Journal:  Neurochem Int       Date:  2016-05-24       Impact factor: 3.921

9.  Distribution of glutamate transporter GLAST in membranes of cultured astrocytes in the presence of glutamate transport substrates and ATP.

Authors:  Jae-Won Shin; Khoa T D Nguyen; David V Pow; Toby Knight; Vlado Buljan; Maxwell R Bennett; Vladimir J Balcar
Journal:  Neurochem Res       Date:  2009-05-08       Impact factor: 3.996

10.  Functional and morphological characterization of glutamate transporters in the rat locus coeruleus.

Authors:  M C Medrano; I Gerrikagoitia; L Martínez-Millán; A Mendiguren; J Pineda
Journal:  Br J Pharmacol       Date:  2013-08       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.